The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | An unmet need: reducing early death in amyloidosis
Around a quarter of new amyloidosis patients die within 6 months of diagnosis, and, despite large pharmacological and technological advancements, this statistic has not improved over the past three decades. Here, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, highlights two of the primary requirements of future amyloidosis research in order to reduce this mortality rate. Dr Wechalekar emphasizes the need to improve awareness of the disease in primary care settings to increase the speed of diagnosis. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
